Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

This study has been completed.
Astellas Pharma Inc
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: December 24, 2009
Last updated: April 4, 2014
Last verified: April 2014
The survey is conducted to collect safety and effectiveness information in Hypertensive patients treated with Micombi Tablets on the long term use in daily clinical settings in Japan.

Condition Intervention
Drug: Telmisartan 80mg
Drug: Telmisartan 40mg
Drug: Hydrochlorothiazide 12.5mg

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Post Marketing Surveillance on Long Drug Use of Micombi Combination Tablets in Patients With Hypertension

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Incidence of Adverse Events (AEs) [ Time Frame: Week 52 ]
    The number of patient with any AEs, patients with drug-related AEs

Secondary Outcome Measures:
  • Systolic Blood Pressure (SBP) [ Time Frame: Week 0 and Week 52 ]
    SBP is observed at Week 0 and Week 52. The change of SBP from Week 0 to Week 52 is calculated.

  • Diastolic Blood Pressure (DBP) [ Time Frame: Week 0 and Week 52 ]
    DBP is observed at Week 0 and Week 52. The change of DBP from Week 0 to Week 52 is calculated.

  • Target Blood Pressure Achievement Rate [ Time Frame: Week 52 ]
    The proportion of the patients with target blood pressure in 52 weeks administrative period. Target blood pressure is defined as 'Guidelines for the management of hypertension (JSH2009)': less than 140/90 (SBP/DBP) mmHg for >= 65 years old or cerebrovascular disorder patient; less than 130/80 in diabetes, chronic kidney disease or myocardial infarction patient; less than 130/85 mmHg for others patient.

  • Blood Pressure Normalised Rate [ Time Frame: Week 52 ]
    The proportion of the patients with normalized blood pressure in 52 weeks on administrative period. Normalized blood pressure is defined less than 140/90 (SBP/DBP) mmHg according to JSH2009

Enrollment: 1452
Study Start Date: January 2010
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Micombi® Combination Tablet AP Drug: Telmisartan 40mg
Combination tablet
Drug: Hydrochlorothiazide 12.5mg
Combination tablet
Micombi® Combination Tablet BP Drug: Telmisartan 80mg
Combination tablet
Drug: Hydrochlorothiazide 12.5mg
Combination tablet


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Inclusion criteria:

Hypertensive patients who have never taken Micombi Tablets.

Exclusion criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01050062

  Show 314 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim
Astellas Pharma Inc
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim Identifier: NCT01050062     History of Changes
Other Study ID Numbers: 502.542
Study First Received: December 24, 2009
Results First Received: December 18, 2012
Last Updated: April 4, 2014

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists processed this record on May 22, 2017